140 related articles for article (PubMed ID: 38467342)
21. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
22. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
23. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
24. Optimized Hypofractionation Can Markedly Improve Tumor Control and Decrease Late Effects for Head and Neck Cancer.
Shuryak I; Hall EJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):272-278. PubMed ID: 30776451
[TBL] [Abstract][Full Text] [Related]
25. Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria.
Snyder JE; Willett AB; Sun W; Kim Y
Pract Radiat Oncol; 2019 Mar; 9(2):e156-e163. PubMed ID: 30415074
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
27. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve.
Wang PM; Chung NN; Hsu WC; Chang FL; Jang CJ; Scorsetti M
Rep Pract Oncol Radiother; 2015; 20(6):417-24. PubMed ID: 26696781
[TBL] [Abstract][Full Text] [Related]
30. Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models.
Li QW; Qiu B; Wang B; Zhang J; Chen L; Zhou Y; Qin JK; Guo SP; Xie WH; Hui ZG; Liang Y; Guo JY; Wang H; Zhu M; Shen WT; Duan LY; Chen LK; Zhang L; Long H; Wang YM; Liu H
Radiother Oncol; 2019 Jul; 136():98-105. PubMed ID: 31015136
[TBL] [Abstract][Full Text] [Related]
31. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma.
Park JH; Yoon SM; Lim YS; Kim SY; Shim JH; Kim KM; Lee HC; Cho B; Park G; Kim JH
J Gastroenterol Hepatol; 2013 Oct; 28(10):1638-42. PubMed ID: 23621519
[TBL] [Abstract][Full Text] [Related]
32. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
[TBL] [Abstract][Full Text] [Related]
33. Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning of head and neck cancers.
Quashie EE; Li XA; Prior P; Awan M; Schultz C; Tai A
Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37903437
[No Abstract] [Full Text] [Related]
34. Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma.
Park J; Jung J; Kim D; Jung IH; Park JH; Kim JH; Lee SW; Yoon SM
BMC Cancer; 2018 Oct; 18(1):1040. PubMed ID: 30367606
[TBL] [Abstract][Full Text] [Related]
35. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma.
Jeong Y; Jung J; Cho B; Kwak J; Jeong C; Kim JH; Park JH; Kim SY; Shim JH; Kim KM; Lim YS; Lee HC; Yoon SM
BMC Cancer; 2018 Apr; 18(1):416. PubMed ID: 29653562
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma.
Park S; Jung J; Cho B; Kim SY; Yun SC; Lim YS; Lee HC; Park J; Park JH; Kim JH; Yoon SM
J Gastroenterol Hepatol; 2020 Nov; 35(11):1953-1959. PubMed ID: 32052884
[TBL] [Abstract][Full Text] [Related]
38. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
39. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
